在以色列检测到一种独特的新冠病毒刺突蛋白P681H变体。
A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel.
作者信息
Zuckerman Neta S, Fleishon Shay, Bucris Efrat, Bar-Ilan Dana, Linial Michal, Bar-Or Itay, Indenbaum Victoria, Weil Merav, Lustig Yaniv, Mendelson Ella, Mandelboim Michal, Mor Orna, Zuckerman Neta
机构信息
Central Virology Laboratory, Israel Ministry of Health, Sheba Medical Center, Tel-Hashomer 52621, Israel.
Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
出版信息
Vaccines (Basel). 2021 Jun 8;9(6):616. doi: 10.3390/vaccines9060616.
The routine detection, surveillance, and reporting of novel SARS-CoV-2 variants is crucial, as these threaten to hinder global vaccination efforts. Herein we report a novel local variant with a non-synonymous mutation in the spike (S) protein P681H. This local Israeli variant was not associated with a higher infection rate or higher prevalence. Furthermore, the local variant was successfully neutralized by sera from fully vaccinated individuals at a comparable level to the B.1.1.7 variant and an Israel wild-type strain. While it is not a variant of concern, routine monitoring by sequencing is still required.
新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的常规检测、监测和报告至关重要，因为这些变体可能会阻碍全球疫苗接种工作。在此，我们报告一种新型本地变体，其刺突（S）蛋白存在P681H非同义突变。这种以色列本地变体与更高的感染率或更高的流行率无关。此外，来自完全接种疫苗个体的血清能够以与B.1.1.7变体和以色列野生型毒株相当的水平成功中和这种本地变体。虽然它不是一个值得关注的变体，但仍需要通过测序进行常规监测。
Zotero 插件